Artesunate ( DrugBank: Artesunate )

3 diseases

18. 脊髄小脳変性症（多系統萎縮症を除く。）

臨床試験数 : 76 / 薬物数 : 98 - (DrugBank : 31) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 65

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04921930 (ClinicalTrials.gov)	July 1, 2021	31/5/2021	Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA)	Evaluation of the Effect of Artesunatein Friedreich Ataxia (FA) Phase I-II Efficacy-Toxicity of Arte ...	Friedreich Ataxia	Drug: Artesunate Oral Product	Institut National de la Santé Et de la Recherche Médicale, France	Imagine Institute	Not yet recruiting	16 Years	65 Years	Male	20	Phase 1/Phase 2	NULL
2	EUCTR2021-000171-36-FR (EUCTR)	23/03/2021	22/01/2021	PHASE I-II EFFICACY-TOXICITY OF ARTESUNATE IN FRIEDREICH ATAXIA (FA)	PHASE I-II EFFICACY-TOXICITY OF ARTESUNATE IN FRIEDREICH ATAXIA	Friedreich Ataxia MedDRA version: 20.0;Level: PT;Classification code 10017374;Term: Friedreich's ata ...	Product Name: artesunate	INSERM	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	22	Phase 1;Phase 2	France

臨床試験数 : 275 / 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2000038104	2020-09-01	2020-09-10	Efficacy and safety of Artesunatefor patients with IgA nephropathy: a multicenter, double-blind, ran ...	Efficacy and safety of Artesunatefor patients with IgA nephropathy: a multicenter, double-blind, ran ...	IgA nephropathy	Group 1:Artesunate 100mg (50mg/Bid);Group 2:Artesunate 50mg (25mg/Bid);The control group:Placebo;	Dongzhimen Hospital, The First Affiliated Hospital of Beijing University of Chinese Medicine	NULL	Recruiting			Both	Group 1:40;Group 2:40;The control group:40;		China

臨床試験数 : 2,442 / 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04713631 (ClinicalTrials.gov)	January 21, 2021	3/12/2020	Safety and Efficacy of Artesunate & Curcumin in Crohn's Disease	Phase 2a Randomised Double-blind Placebo-controlled Trial to Assess Safety, Efficacy of Artesunate& ...	Crohn's Disease	Drug: Artesunate;Drug: Curcumin;Drug: Placebo A;Drug: Placebo C	Sanjay Gandhi Postgraduate Institute of Medical Sciences	St George's University of London, London, UK	Recruiting	18 Years	65 Years	All	40	Phase 2	India